 Argenx SEs NASDAQ: ARGX Phase 3 ADVANCE trial of Vyvgart efgartigimod alfa-fcab in adults with primary immune thrombocytopenia ITP met its primary endpoint. The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP. 